126 related articles for article (PubMed ID: 11474273)
1. Pharmacologic study of paclitaxel administered with or without the cytoprotective agent amifostine, and given as a single agent or in combination with epirubicin and cisplatin in patients with advanced solid tumors.
Van den Brande J; Nannan Panday VR; Hoekman K; Rosing H; Huijskes RV; Verheijen RH; Beijnen JH; Vermorken JB
Am J Clin Oncol; 2001 Aug; 24(4):401-3. PubMed ID: 11474273
[TBL] [Abstract][Full Text] [Related]
2. Influence of the cyto-protective agent amifostine on the pharmacokinetics of low-dose Paclitaxel.
Juan O; Rocher A; Sánchez A; Sánchez JJ; Alberola V
Chemotherapy; 2005 Jul; 51(4):200-5. PubMed ID: 15985759
[TBL] [Abstract][Full Text] [Related]
3. Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group.
Moore DH; Donnelly J; McGuire WP; Almadrones L; Cella DF; Herzog TJ; Waggoner SE;
J Clin Oncol; 2003 Nov; 21(22):4207-13. PubMed ID: 14615449
[TBL] [Abstract][Full Text] [Related]
4. Assessment of amifostine as protection from chemotherapy-induced toxicities after conventional-dose and high-dose chemotherapy in patients with germ cell tumor.
Rick O; Beyer J; Schwella N; Schubart H; Schleicher J; Siegert W
Ann Oncol; 2001 Aug; 12(8):1151-5. PubMed ID: 11583199
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics and metabolism of paclitaxel after polychemotherapy with the cytoprotective agent amifostine.
Czejka M; Schueller J; Eder I; Reznicek G; Kraule C; Zeleni U; Freitag R
Anticancer Res; 2000; 20(5C):3871-7. PubMed ID: 11268469
[TBL] [Abstract][Full Text] [Related]
6. The potential of amifostine: from cytoprotectant to therapeutic agent.
Santini V; Giles FJ
Haematologica; 1999 Nov; 84(11):1035-42. PubMed ID: 10553165
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy--a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologoie (AGO) Ovarian Cancer Study Group.
Hilpert F; Stähle A; Tomé O; Burges A; Rossner D; Späthe K; Heilmann V; Richter B; du Bois A;
Support Care Cancer; 2005 Oct; 13(10):797-805. PubMed ID: 16025262
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group.
Frasci G; D'Aiuto G; Comella P; Apicella A; Thomas R; Capasso I; Di Bonito M; Cartenì G; Biglietto M; De Lucia L; Maiorino L; Piccolo S; Bianchi U; D'Aniello R; Lapenta L; Comella G
Breast Cancer Res Treat; 1999 Aug; 56(3):239-52. PubMed ID: 10573115
[TBL] [Abstract][Full Text] [Related]
9. Carboplatin and paclitaxel in non-small cell lung cancer: the role of amifostine.
Selvaggi G; Belani CP
Semin Oncol; 1999 Apr; 26(2 Suppl 7):51-60. PubMed ID: 10348261
[TBL] [Abstract][Full Text] [Related]
10. Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer.
Antonadou D; Throuvalas N; Petridis A; Bolanos N; Sagriotis A; Synodinou M
Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):402-8. PubMed ID: 12957251
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.
Movsas B; Scott C; Langer C; Werner-Wasik M; Nicolaou N; Komaki R; Machtay M; Smith C; Axelrod R; Sarna L; Wasserman T; Byhardt R
J Clin Oncol; 2005 Apr; 23(10):2145-54. PubMed ID: 15800308
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma.
Amrein PC; Clark JR; Supko JG; Fabian RL; Wang CC; Colevas AD; Posner MR; Deschler DG; Rocco JW; Finkelstein DM; McIntyre JF
Cancer; 2005 Oct; 104(7):1418-27. PubMed ID: 16116597
[TBL] [Abstract][Full Text] [Related]
13. Amifostine before chemotherapy: improved tolerance profile of the subcutaneous over the intravenous route.
Koukourakis MI; Simopoulos C; Minopoulos G; Patlakas G; Polychronidis A; Limberis V; Romanides K; Pitiacoudis M; Manolas C
Clin Cancer Res; 2003 Aug; 9(9):3288-93. PubMed ID: 12960114
[TBL] [Abstract][Full Text] [Related]
14. Effects of amifostine and paclitaxel on growth of human ovarian carcinoma xenografts in the severe combined immune-deficient mouse: preliminary results.
Paine GD; Taylor CW; Lopez MH; Johnson CS; Capizzi RL
Semin Oncol; 1996 Aug; 23(4 Suppl 8):35-9. PubMed ID: 8783664
[TBL] [Abstract][Full Text] [Related]
15. Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer.
Garces YI; Okuno SH; Schild SE; Mandrekar SJ; Bot BM; Martens JM; Wender DB; Soori GS; Moore DF; Kozelsky TF; Jett JR
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):995-1001. PubMed ID: 17336213
[TBL] [Abstract][Full Text] [Related]
16. The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumors.
Hartmann JT; Knop S; Fels LM; van Vangerow A; Stolte H; Kanz L; Bokemeyer C
Anticancer Drugs; 2000 Jan; 11(1):1-6. PubMed ID: 10757556
[TBL] [Abstract][Full Text] [Related]
17. Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer.
Jary M; Ghiringhelli F; Jacquin M; Fein F; Nguyen T; Cleau D; Nerich V; El Gani M; Mathieu P; Valmary-Degano S; Arnould L; Lassabe C; Lamfichekh N; Fratté S; Paget-Bailly S; Bonnetain F; Borg C; Kim S
Cancer Chemother Pharmacol; 2014 Jul; 74(1):141-50. PubMed ID: 24824852
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer.
Gelmon K; Eisenhauer E; Bryce C; Tolcher A; Mayer L; Tomlinson E; Zee B; Blackstein M; Tomiak E; Yau J; Batist G; Fisher B; Iglesias J
J Clin Oncol; 1999 Oct; 17(10):3038-47. PubMed ID: 10506598
[TBL] [Abstract][Full Text] [Related]
19. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer.
Leong SS; Tan EH; Fong KW; Wilder-Smith E; Ong YK; Tai BC; Chew L; Lim SH; Wee J; Lee KM; Foo KF; Ang P; Ang PT
J Clin Oncol; 2003 May; 21(9):1767-74. PubMed ID: 12721253
[TBL] [Abstract][Full Text] [Related]
20. A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation.
Hartmann JT; von Vangerow A; Fels LM; Knop S; Stolte H; Kanz L; Bokemeyer C
Br J Cancer; 2001 Feb; 84(3):313-20. PubMed ID: 11161394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]